A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 26, 2020

Primary Completion Date

March 31, 2022

Study Completion Date

July 28, 2022

Conditions
Pleural Effusion
Interventions
DRUG

LTI-01

single-chain urokinase plasminogen activator, scuPA

DRUG

Placebo

normal saline

Trial Locations (33)

11040

North Shore - Long Island Jewish Medical Center, Queens

17033

The Pennsylvania State University, Hershey

19104

University of Pennsylvania, Philadelphia

19140

Temple University, Philadelphia

21201

University of Maryland School of Medicine, Baltimore

21205

Johns Hopkins University, Baltimore

22031

INOVA, Fairfax

23219

Virginia Commonwealth University, Richmond

27599

University of North Carolina at Chapel Hill, Chapel Hill

27705

Duke University, Durham

35294

The University of Alabama at Birmingham, Birmingham

37232

Vanderbilt Medical Center, Nashville

39216

University of Mississippi Medical Center, Jackson

43210

The Ohio State University, Columbus

48109

University of Michigan, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

60612

Rush University Medical Center, Chicago

63110

Washington University, St Louis

64111

St. Luke's Health System, Kansas City

66160

The University of Kansas Medical Center, Kansas City

68124

CHI CUMC Bergan Mercy, Omaha

75390

The University of Texas Southwestern Medical Center, Dallas

77030

The University of Texas Health Science Center, Houston

80445

University of Colorado, Aurora

84112

University of Utah, Salt Lake City

90095

University of California (UCLA), Los Angeles

92037

UC San Diego Health Jacobs Medical Center, La Jolla

95816

UC Davis Medical Group, Sacramento

06519

Yale School of Medicine, New Haven

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01805

Lahey Hospital and Medical Center, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Rein Therapeutics

INDUSTRY

NCT04159831 - A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions | Biotech Hunter | Biotech Hunter